EARS2: A Potential Drug Target and Biomarker for Glutamyl-TRNA Synthetase in Mitochondria

Target Name: EARS2

NCBI ID: G124454

EARS2

EARS2: A Potential Drug Target and Biomarker for Glutamyl-TRNA Synthetase in Mitochondria

Glutamyl-tRNA synthetase (GTS) is a key enzyme in the regulation of protein synthesis in the cell. It is a mitochondrial protein that functions to convert glutamyl-CoA, a highly reactive amino acid, into its biologically active form, glutamyl-tRNA. GTS is essential for the synthesis of proteins involved in various cellular processes such as cell growth, apoptosis, and stress responses. The dysfunction of GTS has been implicated in various diseases, including cancer, neurodegenerative diseases, and systemic inflammatory diseases.

The protein encoded by the EARS2 gene is a member of the GTPase-activating protein (GAP) family and is highly conserved in its sequence and structure. It is a 21 kDa protein that is expressed in various tissues and organs, including brain, heart, and muscle. EARS2 has been shown to play a crucial role in the regulation of protein synthesis and to be involved in various cellular processes, including cell growth, apoptosis, and stress responses.

GTS is a protein that is expressed in the mitochondria and is involved in the synthesis of glutamyl-tRNA. It is a key enzyme in the regulation of protein synthesis in the cell and is required for the proper functioning of various cellular processes. GTS has been shown to play a crucial role in the regulation of cell growth and apoptosis, as well as in the response to stress and oxidative stress.

Studies have suggested that alterations in the levels of GTS have been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and systemic inflammatory diseases. For example, GTS has been shown to be involved in the regulation of cancer cell growth and has been identified as a potential drug target for cancer treatment. Similarly, GTS has been implicated in the development and progression of neurodegenerative diseases, including Alzheimer's disease, as well as in the regulation of the immune response.

In addition to its involvement in the regulation of protein synthesis, GTS has also been shown to play a role in the regulation of cell apoptosis. GTS has been shown to be involved in the regulation of apoptosis-associated protein (AP-1) expression and in the regulation of cell cycle progression.

GTS has also been shown to be involved in the regulation of the immune response. GTS has been shown to be involved in the regulation of the production of immune cell populations, including T cells, and has been implicated in the development of autoimmune diseases.

EARS2 has also been shown to play a role in the regulation of protein synthesis and to be involved in various cellular processes, including cell growth, apoptosis, and stress responses. It is a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and systemic inflammatory diseases.

In conclusion, EARS2 is a protein that is involved in the regulation of protein synthesis in the cell and is considered a potential drug target for various diseases. Its role in the regulation of cell growth, apoptosis, and stress responses makes it an attractive target for cancer and neurodegenerative diseases. Further research is needed to fully understand the role of EARS2 in cellular processes and to develop effective treatments for diseases associated with its dysfunction.

Protein Name: Glutamyl-tRNA Synthetase 2, Mitochondrial

Functions: Catalyzes the attachment of glutamate to tRNA(Glu) in a two-step reaction: glutamate is first activated by ATP to form Glu-AMP and then transferred to the acceptor end of tRNA(Glu)

The "EARS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EARS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets